Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats.
MAbs
; 12(1): 1752529, 2020.
Article
en En
| MEDLINE
| ID: mdl-32316838
ABSTRACT
The success of therapeutic antibodies is largely attributed for their exquisite specificity, homogeneity, and functionality. There is, however, a need to engineer antibodies to extend and enhance their potency. One parameter is functional affinity augmentation, since antibodies matured in vivo have a natural affinity threshold. Generation of multivalent antibodies is one option capable of surpassing this affinity threshold through increased avidity. In this study, we present a novel platform consisting of an array of multivalent antibody formats, termed Quads, generated using the self-assembling tetramerization domain from p53. We demonstrate the versatility of this tetramerization domain by engineering anti-tumor necrosis factor (TNF) Quads that exhibit major increases in binding potency and in neutralizing TNF-mediated cytotoxicity compared to parental anti-TNF molecules. Further, Quads are amenable to fusion with different binding domains, allowing generation of novel multivalent monospecific and bispecific formats. Quads are thus a novel group of molecules that can be engineered to yield potential therapeutics with novel modalities and potencies.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Ingeniería de Proteínas
/
Anticuerpos Biespecíficos
/
Multimerización de Proteína
/
Anticuerpos Monoclonales
/
Afinidad de Anticuerpos
Límite:
Animals
/
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article